Sarepta Therapeutics (SRPT) Stock Price, Quote & News

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dyst...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 274 4000

Website: www.sarepta.com

Address:

215 First Street, Suite 415, Cambridge, United States

WeAreKangz Aug. 24 at 1:25 AM

$SRPT one thing to watch with capr. Their drug should realistically get zero chance e of approval under all previous fda precedent. If they get it, I don’t want to hear a damn concern about PMOs or non amb not returning lol, would prove the fda standards dropped. Cape’s success is setting up sarepta without a direct competitor for our space in DMD.

1 · Reply

USAEquityResearch Aug. 23 at 11:43 AM

$SRPT 📊 USAEquityResearch ▼ 18.79 (-2.24%) Trend: Bullish 📈 RSI (14): 71.8 — overbought, extended, caution warranted MACD: bullish, above signal line and rising Volume: below average 📌 Key Levels Resistance: 19.73 | Support: 14.86 20-MA: 17.16 | 50-MA: 17.29 💼 Fundamentals Mkt Cap: $1.98B Fwd P/E: 7.3 FCF: $22.14M (0.21/sh) Total Debt: $1.06B D/E: 69.54 📉 Options (exp 2026-08-28) ATM IV: 62.1% | Skew: +10.2% (put-heavy) P/C Ratio: 0.14 🐂 Bullish lean Max Pain: 17.50 Call wall: 19.00 | Put wall: 17.50 Educational content only. Not financial advice. Full data, options chain & financials: https://usaequityresearch.com/stocks/SRPT

0 · Reply

Thaigrlsrk Aug. 23 at 2:29 AM

$SRPT Best short out there for tomorrow FC1:COM . Ranchers dancing with who brung em now.

0 · Reply

Roaring_Capybara Aug. 22 at 5:37 PM

$SRPT My Sarepta view: No 2 body chemistries are the same – some people have and others will continue to die from complications of seasonal flu vaccines. Overall, flu vaccines are sanctioned as a play against the odds. As such, non-ambulatory “odds” are still excellent and eventually Sarepta will regain that market share. In the meantime, they are a biotech with 1) Strong Revenue and 2) An outstanding siRNA pipeline. They timed their agreement with ARWR and picked some plums from their pipeline. ARWR has since gone up 400%. To be a biotech with ANY revenue is rare. To have that and an outstanding pipeline is a dream scenario. In summary: Buy Sarepta before the bargain sale quickly fades.

0 · Reply

Thaigrlsrk Aug. 21 at 11:38 PM

$SRPT Mid September is when we will know if FSHD or DM1 made the late breaker for WMS. Shorts will know more then likely on Sept. 11. This is when notifications are sent. The author will know sooner depending on when they are accepted. If one of the Two or both make it. There will be a short exit, toot suite.

2 · Reply

fpak Aug. 21 at 7:53 PM

$SRPT Oh well. We all knew this was going to happen. See you at 16.

1 · Reply

WeAreKangz Aug. 21 at 7:52 PM

$SRPT low volume sell off so clean you can trace a straight line down the top of each candle. Zero human hands exchanged shares today, all algos. Days without news are just going to be subject to this, can’t escape it

0 · Reply

KY3000 Aug. 21 at 7:06 PM

$SRPT this is diarrhea, aka loose booty

0 · Reply

fpak Aug. 21 at 6:36 PM

$SRPT The turd is strong in this one.

0 · Reply

Allrisknobrakes Aug. 21 at 6:35 PM

$SRPT The volume has just fallen off a cliff (except the day of new FDA hire). Like it was getting 3M a day. Now we are lucky to see 2M a day unless there is a news event

0 · Reply

Sarepta Therapeutics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 18 days ago

Sarepta Therapeutics Quarterly report: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 18 days ago

Sarepta Therapeutics Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 18 days ago

Sarepta Therapeutics Slides: Q2 2026

Aug 5, 2026, 4:05 PM EDT - 18 days ago

Market Cap	1.98B
Revenue (ttm)	2.20B
Net Income (ttm)	-713.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	5.61
Profit Margin	-32.45%
Debt to Equity Ratio	0.55

Volume	1,674,500
Avg Vol	3,408,440
Day's Range	N/A - N/A
Shares Out	105.63M
Stochastic %K	53%
Beta	0.23
Analysts	Sell
Price Target	$22.00